Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.77 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.77 |
| ▸ | HTR1A | P08908 | 1/20 | 0.77 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.77 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896989 | 0.94 | ELANE (0.80) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL7905406 | 0.90 | ELANE (0.82) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL10013429 | 0.90 | ELANE (0.82) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL1245778 | 0.89 | ELANE (0.74) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL14899925 | 0.88 | ELANE (0.89) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| Bay-678 SCHEMBL1245235 | 0.87 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL1245423 | 0.87 | ELANE (0.87) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| Bay-677 SCHEMBL4179543 | 0.87 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| Bay-678 SCHEMBL1245297 | 0.87 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL1245171 | 0.86 | ELANE (0.85) | ELANECYP2C9ADRB1HTR1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546113-B1 | PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES | BAYER IP GMBH (DE) | 2013-05-01 | — | — | EP | disclosed |